Dr. Ronan Kelly Q&A: Clinical Trial Results Show Immunotherapy’s Potential in Resectable Esophageal and Gastroesophageal Junction Cancers
The results of a study published today in Nature Medicine show exciting immune responses in patients with operable esophageal or gastroesophageal cancers given neoadjuvant immunotherapy. The study results also show the potential for monitoring circulating tumor DNA as a predictor for future intervention.